New Approach Could Boost Immunotherapy for Breast Cancer

Immunotherapy has been less effective against breast cancer than other cancers. Researchers think regulatory T (Treg) cells are restraining the immune system from mounting an adequate attack against breast tumors. New research identifies a protein in specific Treg cells that could serve as a therapeutic target.

Highlights

Immunotherapy has been less effective against breast cancer.

Regulatory T cells may be hampering its effectiveness.

Targeting a protein in these cells may eliminate them.

This could make breast cancer immunotherapy work better.

Though immunotherapy has produced impressive results against many malignancies, it has been less effective against breast cancer. Researchers think one reason for this may be the influence of a subset of immune cells called regulatory T (Treg) cells. These cells, which tamp down the immune response, are especially prevalent in breast cancer and are associated with more aggressive forms of the disease.

New research led by MSK physician-scientist George Plitas, graduate student Catherine Konopacki, and co-authors and reported in the journal Immunitysuggests a promising approach for targeting these Treg cells to make breast cancer immunotherapy more potent. The strategy might make it possible to take specific Treg cells out of the equation so that other immune cells can wipe out the breast tumor.

Treg cells help rein in immune responses once they are no longer needed, preventing an attack on the body’s healthy tissues — what is called autoimmunity. Although essential to maintaining order, Treg cells also thwart the immune system from attacking tumors, which might otherwise be recognized as foreign or as different.

How does focusing on Treg cells differ from immunotherapies that have shown success in recent years?

The drugs that have worked so well against melanoma, lung cancer, kidney cancer, and bladder cancer are checkpoint inhibitors, which block receptors on the surface of a type of immune cell called effector T cells. This “releases the brakes” on these immune cells and allows them to attack anything that appears foreign. These drugs are effective because they need to inhibit just one specific immune cell pathway.

Treg cells, by contrast, appear to operate through many different pathways, meaning that they suppress the immune response through multiple mechanisms. Blocking just one of those will likely not be effective. We’ve always thought that the best way to target Treg cells is simply to get rid of them.

Immunotherapy at MSK

Cancer is smart, but your immune system is smarter. Discover how Memorial Sloan Kettering is deploying immunotherapy to fight cancer.

However, it’s very hard to target only Treg cells selectively. Some ways that have been tried were relatively nonspecific in that they took out other T cells — including effector T cells — that are needed for an immune attack. In addition, even if you target only Treg cells, you don’t want to get rid of all of them — that can cause massive autoimmunity, which is lethal.

What strategy could be used to target only certain Treg cells?

The Holy Grail is to find a way to target only those Treg cells that are in or next to tumors, while not affecting other Treg cells that are circulating in the blood. But we realized we really needed to learn more about these “tumor-resident” and “tissue-resident” Treg cells because most of what we know about human Treg cells has come from those circulating in the blood, simply because they are much more accessible.

Presumably, taking out these Treg cells would leave the tumor more vulnerable to attack from the other immune cells.

George PlitasPhysician-scientist

We undertook a project to isolate human Treg cells from normal tissue, tumors, and blood and compare them. The samples were taken from our patients with breast cancer with their consent, and it required tremendous coordination with our core facilities to get them processed and analyzed. But the technology we used enables us to conduct these analyses and get answers quickly.

What did you learn about these specific Treg cells?

We found, somewhat surprisingly, that the patterns of gene expression of the Treg cells in the normal breast tissue are similar to the Treg cells in the breast tumor — but that these patterns are different from those of the Treg cells in the blood. In other words, Treg cells within a specific tissue, regardless of whether it is normal or cancerous, have their own distinct pattern.

At first, this might seem like a major problem: Any therapy aimed at cancer-specific Treg cells could cause problems in the normal tissue. However, we did see some differences between the tissue-resident and tumor-resident Treg cells. Those in the tumors had higher levels of a protein called CCR8. This suggests that targeting the CCR8 protein with an antibody could be effective in selectively depleting the tumor-resident Treg cells. Presumably, taking out these Treg cells would leave the tumor more vulnerable to attack from the other immune cells. This may represent a promising immunotherapeutic approach to treating breast cancer.

What’s the next step in translating these findings to the clinic to actually treat patients?

In our lab, we’re generating antibodies against CCR8 that could be used in clinical trials to see if we can deplete tumor-resident Treg cells. We already have some good contenders. In addition, we have found increased CCR8 expression by Treg cells from other tumor types, including lung cancer and melanoma, so it doesn’t seem to be restricted to breast cancer. I think this strategy could be broadly applicable to a number of different tumor types, used either alone or in some cases in combination with other therapies such as checkpoint blockade.

Treg cells with their multiple suppressive properties will be difficult to block. However, the cancer community believes they are a major obstacle to making immunotherapies work, particularly for cancers where responses have been limited. This is an area of research with a great amount of untapped potential.

Sonya, thank you for reaching out. We passed your question on to Dr. Plitas, who responds:

"Thank you for your comment! Breast cancers are variably infiltrated by immune cells and the triple negative (TN) biologic subtype of breast cancer tends to be much more densely infiltrated than other subtypes. Due to this pre-existing immune response it is hypothesized that TN breast cancers may be more susceptible to immunotherapy than other subtypes and that is why there has been a relative preponderance of immunotherapy trials focused on TN breast cancers. Preliminary early phase clinical trials across the different subtypes of breast cancers suggest that there is greater activity in TN breast cancer. We are trying to understand ways of making other subtypes of breast cancer more susceptible to immunotherapy, our preclinical work on regulatory T cells suggests that this may be possible."

Add new comment

We welcome your questions and comments. While we share many of them with our world-class doctors and researchers, we regret that in order to protect your privacy, we are not able to make personal medical recommendations on this forum, nor do we publish comments that contain your personal information. If you would like to consult with an MSK doctor, we encourage you to make an appointment at 800-525-2225 or request an appointment online.